Lilly and Boehringer’s Trajenta matches glimepiride in delaying cardiovascular events in type 2 diabetes patients
February 15, 2019Medical Communications, Research and Development Boehringer, Eli Lilly, cardiovascular disease, pharma, type 2 diabetes
Boehringer Ingelheim and Eli Lilly’s Trajenta (linagliptin) met its primary endpoint in a recent trial, it has emerged, proving itself …
Top Ten most popular articles on Pharmafile.com this week!
February 15, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AMR, Dame Sally Davies, FDA, FMD, antibiotic resistance, esketamine, falsified medicines, top 10
News that the FDA’s advisory panel had recommended Janssen’s intranasal esketamine spray Spravato as a treatment for treatment resistant depression, …
Roche’s Perjeta secures NICE approval in adjuvant HER2+ metastatic breast cancer
February 15, 2019Medical Communications, Sales and Marketing NICE, Perjeta, Roche, pharma
NICE has announced its decision to authorise the use of Roche’s Perjeta (pertuzumab) on the NHS for the treatment of …
AstraZeneca to retire MedImmune brand amid restructuring
February 15, 2019Medical Communications AstraZeneca, Business, MedImmune, R&D, biologics, restructuring
AstraZeneca is retiring the MedImmune brand as part of a restructuring that will see biologics integrated into two new R&D …
Lundbeck and Otsuka’s bipolar treatment fails Phase 3 trials due to unexpected placebo effect
February 15, 2019Medical Communications CNS, Lundbeck, Otsuka, Rexulti, bipolar disorder, mental health
Lundbeck and Otsuka’s treatment for bipolar disorder, Rexulti, failed to achieve its primary endpoint in two separate Phase 3 trials. …
First asthma pill in two decades could treat condition by reducing airway muscle
February 14, 2019Research and Development asthma, pharma
Researchers at the University of Leicester alongside colleagues in Vancouver, Canada, have revealed data that supports the efficacy of an …
Takeda’s Adcetris secures expanded approval in Europe for untreated CD30+ Stage IV Hodgkin lymphoma
February 14, 2019Sales and Marketing Adcetris, Cancer, Europe, Hodgkin lymphoma, Takeda, pharma
Takeda’s Adcetris (brentuximab vedotin) has seen its marketing authorisation expanded by the European Commission to include the treatment of previously …
FDA approves Novartis’ Egaten for parasitic infection fascioliasis
February 14, 2019Sales and Marketing Egaten, FDA, Novartis, fascioliasis, pharma
The FDA has taken the decision to authorise the use of Novartis’ Egaten (triclabendazole) in patients older than six years …
Clinigen becomes sole license holder of cancer drug Proleukin in $210m deal
February 14, 2019Sales and Marketing Clinigen, Novartis, Proleukin, pharma
Novartis has arranged to sell the remainder of its rights to its skin and lung cancer drug Proleukin (aldesleukin, recombinant …
J&J acquires lung cancer-focused robotics firm Auris Health in potential $5.75m deal
February 14, 2019Manufacturing and Production, Research and Development, Sales and Marketing Auris Health, Cancer, J&J, JJ, lung cancer, pharma, robotics
In a bid to bolster its footing in providing surgical treatments, Johnson & Johnson has announced it will acquire robotics …
BMS scores expanded European approval for Sprycel in paediatric leukaemia
February 13, 2019Research and Development, Sales and Marketing BMS, Cancer, Europe, Sprycel, leukaemia, pharma
Bristol-Myers Squibb’s Sprycel (dasatinib) has secured an expanded indication in Europe, the company said, with the European Commission greenlighting the …
Australian firm Althea enters UK medicinal cannabis market
February 13, 2019Research and Development Epidiolex, GW Pharma, Medical marijuana, NHS, UK, cannabis
Melbourne-based medicinal cannabis company Althea has become one of the first companies to enter the UK market after the British …
Janssen’s esketamine drug recommended by FDA panel for depression
February 13, 2019Research and Development, Sales and Marketing FDA, Janssen, Spravato, depression, esketamine, major depressive disorder, pharma
In a rare and welcomed development in the treatment of major depressive disorder (MDD), Janssen has announced that its esketamine …
Researchers find new type of cell membrane which causes cancer cells to explode
February 13, 2019Research and Development Cancer, FTY720, cell membranes, molecules, oncology
Researchers at the Medical University of South Carolina (MUSC) have discovered a new type of cell membrane complex which causes …
Clinigen shares soar after $210m Novartis cancer drug deal
February 13, 2019Research and Development Cancer, Clinigen, Novartis, Proleukin, UK, US, oncology
British company Clinigen has bought the rights to sell Novartis’ cancer drug Proleukin in the United States in a deal …
Sanofi name current CMO Dr Ameet Nathwani as new Chief Digital Officer
February 12, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
French firm Sanofi has appointed pharma veteran Dr Ameet Nathwani to the position of Chief Digital Officer. In his new …
Gilead’s CAR-T therapy Yescarta rejected for NHS use in Scotland
February 12, 2019Manufacturing and Production, Sales and Marketing CAR-T, Cancer, Gilead, NHS, Scotland, Yescarta, kite pharma
It’s bad news for Scottish patients living with aggressive forms of non-Hodgkin lymphoma (NHL) as it emerges that the Scottish …
Immuno Biotech financial chief found guilty of money laundering
February 12, 2019Manufacturing and Production David Noakes, Dawson-Ball, GcMAF, Guernsey, Immuno Biotech
Peter Edward Dawson-Ball, the financial head of the Guernsey-based firm immuno Biotech, that sold unlicensed blood product GcMAF, has been …
Keytruda + Inlyta combo beats Pfizer’s chemotherapy Sutent in renal cell carcinoma
February 12, 2019Manufacturing and Production, Research and Development Cancer, MSD, Pfizer, inlyta, keytruda, pharma, renal cell carcinoma
New data has been revealed on the efficacy of MSD’s Keytruda (pembrolizumab) in combination with Pfizer’s Inlyta (axitinib), showing it …
FDA to crack down on dietary supplements
February 12, 2019Manufacturing and Production Alzheimer's, Alzheimers, Cancer, Dietary Supplements, FDA, USA, diabetes
The FDA is cracking down on those selling ‘dietary supplements’, having sent warning letters to companies who claim, without proof, …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
